Editorial: Drug development for neglected diseases: a public health challenge

Fehr A, Thuermann P, Razum O (2006)
TROPICAL MEDICINE & INTERNATIONAL HEALTH 11(9): 1335-1338.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ;
Erscheinungsjahr
Zeitschriftentitel
TROPICAL MEDICINE & INTERNATIONAL HEALTH
Band
11
Zeitschriftennummer
9
Seite
1335-1338
ISSN
eISSN
PUB-ID

Zitieren

Fehr A, Thuermann P, Razum O. Editorial: Drug development for neglected diseases: a public health challenge. TROPICAL MEDICINE & INTERNATIONAL HEALTH. 2006;11(9):1335-1338.
Fehr, A., Thuermann, P., & Razum, O. (2006). Editorial: Drug development for neglected diseases: a public health challenge. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 11(9), 1335-1338. doi:10.1111/j.1365-3156.2006.01714.x
Fehr, A., Thuermann, P., and Razum, O. (2006). Editorial: Drug development for neglected diseases: a public health challenge. TROPICAL MEDICINE & INTERNATIONAL HEALTH 11, 1335-1338.
Fehr, A., Thuermann, P., & Razum, O., 2006. Editorial: Drug development for neglected diseases: a public health challenge. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 11(9), p 1335-1338.
A. Fehr, P. Thuermann, and O. Razum, “Editorial: Drug development for neglected diseases: a public health challenge”, TROPICAL MEDICINE & INTERNATIONAL HEALTH, vol. 11, 2006, pp. 1335-1338.
Fehr, A., Thuermann, P., Razum, O.: Editorial: Drug development for neglected diseases: a public health challenge. TROPICAL MEDICINE & INTERNATIONAL HEALTH. 11, 1335-1338 (2006).
Fehr, Angela, Thuermann, Petra, and Razum, Oliver. “Editorial: Drug development for neglected diseases: a public health challenge”. TROPICAL MEDICINE & INTERNATIONAL HEALTH 11.9 (2006): 1335-1338.

6 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Measuring progress in neglected disease drug development.
Cohen JP, Sturgeon G, Cohen A., Clin Ther 36(7), 2014
PMID: 24906971
Expert Delphi survey on research and development into drugs for neglected diseases.
Fehr A, Thürmann P, Razum O., BMC Health Serv Res 11(), 2011
PMID: 22087801
Exploring 3-arylquinoxaline-2-carbonitrile 1,4-di-N-oxides activities against neglected diseases with QSAR.
Vicente E, Duchowicz PR, Ortiz Edel V, Monge A, Castro EA., Chem Biol Drug Des 76(1), 2010
PMID: 20492446
Development of and access to products for neglected diseases.
Cohen J, Dibner MS, Wilson A., PLoS One 5(5), 2010
PMID: 20485552

25 References

Daten bereitgestellt von Europe PubMed Central.


Angell, 2004

Anonymous, The Economist Technology Quarterly (), 2005

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0

Bundesministerium, 2005

CPTech, 2005

Depoortere, 2001

AUTHOR UNKNOWN, 2005

EMEA/COMP, 2005
Two decades of orphan product development.
Haffner ME, Whitley J, Moses M., Nat Rev Drug Discov 1(10), 2002
PMID: 12360259

Hunt, 2003

Liikanen, 2002

Moran, 2005

OrphaNet, 2006

Prodi, 2003
Ethics in health care priority-setting: a north-south double standard?
Stefanini A., Trop. Med. Int. Health 4(11), 1999
PMID: 10588763
Is orphan drug status beneficial to tropical disease control? Comparison of the American and future European orphan drug acts.
Trouiller P, Battistella C, Pinel J, Pecoul B., Trop. Med. Int. Health 4(6), 1999
PMID: 10444316
Drugs for neglected diseases: a failure of the market and a public health failure?
Trouiller P, Torreele E, Olliaro P, White N, Foster S, Wirth D, Pecoul B., Trop. Med. Int. Health 6(11), 2001
PMID: 11703850

Vorholz, 2005

WHO, 2002

AUTHOR UNKNOWN, 0

World, 2006

AUTHOR UNKNOWN, 0

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 16930253
PubMed | Europe PMC

Suchen in

Google Scholar